Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | alloHCT plus fludarabine and treosulfan for secondary AML

Eleni Gavriilaki • 20 Nov 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Fludarabine Treosulfan

Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses a retrospective real-world study exploring whether allogeneic hematopoietic cell transplantation (alloHCT) with a myeloablative conditioning regimen of reduced toxicity, fludarabine and treosulfan (FluTreo), has a long-term survival advantage over previous transplant modalities for secondary acute myeloid leukemia (AML). The results showed the overall survival, relapse rates and graft-versus-host disease were all comparable with FluTreo to other transplants, allowing extension of the allo-HCT eligible population. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Eleni Gavriilaki

The current approach to response assessment in TA-TMA
1:36
The current approach to response assessment in TA-TMA
Eleni Gavriilaki • 25 Mar 2026
The current approach to severity scoring in TA-TMA
1:21
The current approach to severity scoring in TA-TMA
Eleni Gavriilaki • 25 Mar 2026
Moving the field forward in TA-TMA: insights from an educational session
2:26
Moving the field forward in TA-TMA: insights from an educational session
Eleni Gavriilaki • 25 Mar 2026
Endothelial injury syndromes in hematology: unifying the terminology
1:44
Endothelial injury syndromes in hematology: unifying the terminology
Eleni Gavriilaki • 13 Jun 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals